In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL

[1]  T. Griffith,et al.  Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  S. Inoue,et al.  Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.

[3]  Young-ho Kim,et al.  Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. , 2004, Carcinogenesis.

[4]  T. Shiraishi,et al.  Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells , 2004, Oncogene.

[5]  H. Hondermarck,et al.  Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). , 2004, Experimental cell research.

[6]  M. Lamfers,et al.  Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells , 2004, Cancer Gene Therapy.

[7]  S. Bates,et al.  A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. , 2004, Current pharmaceutical design.

[8]  P. Atadja,et al.  Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells , 2004, Cancer Research.

[9]  P. Hersey,et al.  The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. , 2004, Molecular cancer therapeutics.

[10]  J. Neuzil,et al.  Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. , 2004, Biochemical and biophysical research communications.

[11]  A. Sagalowsky,et al.  Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. , 2003, Cancer research.

[12]  Jorge A. Almenara,et al.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.

[13]  M. Grever,et al.  Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. , 2003, Blood.

[14]  J. A. George,et al.  Gene therapy progress and prospects: adenoviral vectors , 2003, Gene Therapy.

[15]  M. MacFarlane.  TRAIL-induced signalling and apoptosis. , 2003, Toxicology letters.

[16]  J. Tschopp,et al.  The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex* , 2002, The Journal of Biological Chemistry.

[17]  H. Wajant,et al.  Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis , 2002 .

[18]  M. Sachs,et al.  Integrin αv and coxsackie adenovirus receptor expression in clinical bladder cancer , 2002 .

[19]  Xiaolu Yang,et al.  c‐FLIPL is a dual function regulator for caspase‐8 activation and CD95‐mediated apoptosis , 2002, The EMBO journal.

[20]  J. Reed,et al.  Downregulation of c-FLIP Sensitizes DU145 Prostate Cancer Cells to Fas-Mediated Apoptosis , 2002, Cancer biology & therapy.

[21]  J. Norris,et al.  Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL , 2002, Cancer Gene Therapy.

[22]  D. Schuppan,et al.  The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. , 2002, Journal of hepatology.

[23]  H. Shu,et al.  The short splice form of Casper/c‐FLIP is a major cellular inhibitor of TRAIL‐induced apoptosis , 2002, FEBS letters.

[24]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[25]  T. Burns,et al.  Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. , 2001, The Journal of biological chemistry.

[26]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  D. Chung,et al.  Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. , 2001, Surgery.

[28]  Peter Scheurich,et al.  NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.

[29]  S. Curley,et al.  Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. , 2001, Cancer research.

[30]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[31]  T. Shimada,et al.  Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. , 2001, Urology.

[32]  R. Price,et al.  Biosafety of in vivo adenovirus-p53 intravesical administration in mice. , 2000, Urology.

[33]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[34]  J. Bergelson.  Receptors mediating adenovirus attachment and internalization. , 1999, Biochemical pharmacology.

[35]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[36]  W. Fair,et al.  The treated natural history of high risk superficial bladder cancer: 15-year outcome. , 1997, The Journal of urology.

[37]  S. Sudarshan,et al.  In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer , 2005, Cancer Gene Therapy.

[38]  C. Voelkel-Johnson.  Sensitizing Tumor Cells by Targeting Death Receptor Signaling Inhibitors , 2005 .

[39]  H. Herr.  Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients , 2005, World Journal of Urology.

[40]  A. D. De Marzo,et al.  Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. , 2002, Urology.